HealthyNCT00800293
Randomized Study to Compare the Bioavailability of Two Augmented Betamethasone Dipropionate 0.05% Topical Creams
An observational study of Healthy, run by Padagis LLC.
Trial summary
The purpose of this study was to compare the relative vasoconstrictive effects of test and reference topical augmented betamethasone dipropionate augmented 0.05% cream in healthy, female subjects. Read more about this study
- Who is it for?
- Ages 18 to 50 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Healthy
- What is being tested?
- Betamethasone Dipropionate 0.05% Cream
- How many people
- 116 participants
- Where
- No sites listed yet
- Study dates
- Dec 2002to Jan 2003
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Women only
- Healthy volunteers accepted
- Adult
Study population: Healthy Community Volunteers
Who may be able to join
- Non-tobacco-using female subjects, 18 to 50 years of age
- Demonstrated blanching response to Reference Drug (augmented betamethasone dipropionate) Cream 0.05%
- Weight within + or - 20% from normal for height and weight for body frame
- Good health as determined by lack of clinically significant abnormalities in medical history and clinical assessment, as judged by the Investigator
- Signed and dated informed consent form which meets all criteria of current FDA regulations
Who cannot join
- History of allergy to systemic or topical corticosteroids
- Presence of any skin condition or coloration that would interfere with the placement of test sites or the response or assessment of skin blanching
- Presence of medical condition requiring regular treatment with prescription drugs
- Drug or alcohol addiction requiring treatment in the past 12 months prior to dosing
- Use of any dermatological drug therapy on the flexor surface of the forearms within 30 days of dosing
- Use of any tobacco products in the 30 days prior to study dosing
- Receipt of any drugs as part of a research study within 30 days prior to study dosing
- Pregnant or lactating
About this study
Official title: Bioequivalence of Two Augmented Betamethasone Dipropionate 0.05% Topical Creams
The purpose of this study was to compare the relative vasoconstrictive effects of test and reference topical augmented betamethasone dipropionate augmented 0.05% cream in healthy, female subjects.
- Conditions
- Healthy
- Being tested
- Betamethasone Dipropionate 0.05% Cream
- Keywords
- bioequivalence, betamethasone dipropionate, Bioequivalency
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Betamethasone Dipropionate 0.05% CreamDrug
Small amount applied and evaluated over the course of several hours
| Study group | Role | What they receive |
|---|---|---|
| Cohort Group 1 | Subject Numbers 1 to 29 Receives: Drug: Betamethasone Dipropionate 0.05% Cream | |
| Cohort Group 2 | Subject Numbers 20 to 59 Receives: Drug: Betamethasone Dipropionate 0.05% Cream | |
| Cohort Group 3 | Subject Numbers 60 to 89 Receives: Drug: Betamethasone Dipropionate 0.05% Cream | |
| Cohort Group 4 | Subject Numbers 90 to 116 Receives: Drug: Betamethasone Dipropionate 0.05% Cream |
What is being measured
The primary outcome is the main question the study is designed to answer.
Vasoconstriction will be measured by the degree of skin blanching observed after treatment removal using a ChromaMeter.
Measured: Over the course of one day
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2008 (estimated)
- Study startDec 2002
- Primary completionJan 2003
- Study completionJan 2003
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for HealthyStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 116 participants (actual)
Sponsor and investigators
- Lead sponsor
- Padagis LLC
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00800293
- Sponsor's protocol ID
- 10216925
- Status last verified
- Oct 2021
- First submitted
- 26 Nov 2008
- Last updated
- 18 Oct 2021
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Oct 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bioequivalence of Two Augmented Betamethasone Dipropionate 0.05% Topical Creams
- ClinicalTrials.gov ID
- NCT00800293
- Acronym / sponsor ID
- 10216925
- Conditions
- Healthy
- Keywords
- bioequivalence, betamethasone dipropionate, Bioequivalency
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 116 participants (actual)
- Lead sponsor
- Padagis LLCIndustry (pharma, biotech, devices)
- Study start
- Dec 2002
- Primary completion
- Jan 2003 (actual)
- Study completion
- Jan 2003 (actual)
- First posted
- 2 Dec 2008 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study was to compare the relative vasoconstrictive effects of test and reference topical augmented betamethasone dipropionate augmented 0.05% cream in healthy, female subjects.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Cohort Group 1 | – | Drug: Betamethasone Dipropionate 0.05% CreamSubject Numbers 1 to 29 |
| Cohort Group 2 | – | Drug: Betamethasone Dipropionate 0.05% CreamSubject Numbers 20 to 59 |
| Cohort Group 3 | – | Drug: Betamethasone Dipropionate 0.05% CreamSubject Numbers 60 to 89 |
| Cohort Group 4 | – | Drug: Betamethasone Dipropionate 0.05% CreamSubject Numbers 90 to 116 |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Healthy Community Volunteers
Key inclusion criteria (5 listed)
- Non-tobacco-using female subjects, 18 to 50 years of age
- Demonstrated blanching response to Reference Drug (augmented betamethasone dipropionate) Cream 0.05%
- Weight within + or - 20% from normal for height and weight for body frame
- Good health as determined by lack of clinically significant abnormalities in medical history and clinical assessment, as judged by the Investigator
- Signed and dated informed consent form which meets all criteria of current FDA regulations
Key exclusion criteria (8 listed)
- History of allergy to systemic or topical corticosteroids
- Presence of any skin condition or coloration that would interfere with the placement of test sites or the response or assessment of skin blanching
- Presence of medical condition requiring regular treatment with prescription drugs
- Drug or alcohol addiction requiring treatment in the past 12 months prior to dosing
- Use of any dermatological drug therapy on the flexor surface of the forearms within 30 days of dosing
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Betamethasone Dipropionate 0.05% CreamSmall amount applied and evaluated over the course of several hours | Drug | Cohort Group 1, Cohort Group 2, Cohort Group 3, Cohort Group 4 |
Primary outcome
Vasoconstriction will be measured by the degree of skin blanching observed after treatment removal using a ChromaMeter.
Time frame: Over the course of one day
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Oct 2021.
Related trials for Healthy
Active, not recruitingObservational study
SCIVAX: Biomarkers of Immune Dysfunction and Vaccine Responsiveness in Chronic SCI
Spinal Cord Injuries, Traumatic Spinal Cord Injury
Recruiting
Effects of a Hemp Seed-based Product on Appetite and Health Parameters
Healthy
RecruitingPhase 1
A Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASH
Metabolic Dysfunction-Associated Steatohepatitis
Not yet recruitingPhase 1
Phase I Trial of High-Density Theta Burst Stimulation (hdTBS)
Healthy Volunteers
Not yet recruiting
Stearic Acid and Endothelial Function
Healthy Middle-aged Subjects, Obesity & Overweight
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Healthy, run by Padagis LLC.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Vasoconstriction will be measured by the degree of skin blanching observed after treatment removal using a ChromaMeter. (time frame: Over the course of one day). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Oct 2021.